Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Treatment and Diagnosis of Cancer, Diabetes and other Disorders Using Adrenomedullin Peptides and Antibodies

Posted Apr 30 2008 5:00pm

Description of Invention:
Adrenomedullin (AM), a 52-amino acid regulatory peptide, is expressed in a wide range of tissues, and has a variety of biological roles. AM was initially identified as a vasodilator, and the effects of AM and its fragments in the cardiovascular system have been widely studied. AM also has important effects on renal function, cell growth, glucose metabolism, and regulation of hormone secretion, and has antimicrobial activity.

This technology claims AM peptides and antibodies, which would be useful in the development of a therapeutic or for diagnostics use. Also claimed are methods of inhibiting tumor cell growth using AM peptides, in particular in a patient suffering from a lung tumor. Claims are also directed to methods of treating a subject with AM-associated conditions, including diabetes, pregnancy, neurological disease, inflammation, or bone development. Finally, methods are claimed for diagnosing or monitoring a disease where AM levels are altered.

Also available is a murine monoclonal antibody, MoAb-G6, which was raised against an AM peptide. This antibody neutralizes AM bioactivity, and reacts with the processed form of AM, but not the preprohormone. This antibody would be useful not only for research use, but also as part of a diagnostic assay for measurement or detection of AM.

Applications:
  • Peptide- or antibody-based therapeutics for cancer, diabetes, inflammation or other AM-associated disease
  • Diagnostic tools for the detection of AM-positive tumors or other AM-associated conditions
  • Research use of AM peptides and antibodies


Development Status:
This technology is currently in the pre-clinical stage of development.

Inventors:
Frank F Cuttitta (NCI)


Patent Status:
HHS, Reference No. E-206-1995/3
US, , Patent No. 6,320,022, Issued 20 Nov 2001
US, , Patent No. 7,101,548, Issued 05 Sep 2006
HHS, Reference No. E-206-1995/3
US, , Patent No. 7,622,272, Issued 24 Nov 2009
PCT, Application No. PCT/US96/13286 filed 16 Aug 1996
US, Application No. 12/569,821 filed 29 Sep 2009


Related Technologies:
EIR, Reference No. E-256-1999/0
EIR, Reference No. E-294-2002/0
US, Application No. 60/153,397 filed 10 Sep 1999, Reference No. E-256-1999/0
US, Application No. 60/425,018 filed 07 Nov 2002, Reference No. E-294-2002/0
US, Patent No. 7,462,593, Issued 09 Dec 2008, Reference No. E-294-2002/0
PCT, Application No. PCT/US00/24722 filed 08 Sep 2000, Reference No. E-256-1999/0
US, Patent No. 7,659,081, Issued 09 Feb 2010, Reference No. E-256-1999/0
US, Application No. 12/240,656 filed 29 Sep 2008, Reference No. E-294-2002/0
US, Application No. 12/638,747 filed 15 Dec 2009, Reference No. E-256-1999/0


Relevant Publication:
  1. A Martínez et al. Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology. 1996 Jun;137(6):2626-2632. [ PubMed abs ]
  2. E Zudaire et al. The central role of adrenomedullin in host defense. J Leukoc Biol. 2006 Aug;80(2):237-244. [ PubMed abs ]
  3. E Zudaire et al. Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol. 2006 Jan;168(1):280-291. [ PubMed abs ]


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Cancer Institute Angiogenesis Core Facility is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Use of Adrenomedullin Peptides and Antibodies in the Treatment and Diagnosis of Cancer, Diabetes and other Disorders. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Cancer
Cancer - Therapeutics
Infectious Diseases
Infectious Diseases - Therapeutics
Internal Medicine
Internal Medicine - Therapeutics
Central Nervous System
Central Nervous System - Therapeutics



For Additional Information Please Contact:
Tara Kirby Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: tk200h@nih.gov
Phone: 301-435-4426
Fax: 301-402-0220


Ref No: 390

Updated: 05/2008

Post a comment
Write a comment: